Caprock Group Has Upped By $350,000 Its Health Ins Innovations (HIIQ) Stake; Last Week Allergy Therapeutics plc (LON:AGY) Coverage

February 19, 2018 - By Vivian Park

Caprock Group Inc increased Health Ins Innovations Inc (HIIQ) stake by 166.67% reported in 2017Q3 SEC filing. Caprock Group Inc acquired 25,000 shares as Health Ins Innovations Inc (HIIQ)’s stock rose 14.56%. The Caprock Group Inc holds 40,000 shares with $580,000 value, up from 15,000 last quarter. Health Ins Innovations Inc now has $496.28M valuation. The stock decreased 3.38% or $1.05 during the last trading session, reaching $30. About 645,710 shares traded or 54.14% up from the average. Health Insurance Innovations, Inc. (NASDAQ:HIIQ) has risen 227.83% since February 19, 2017 and is uptrending. It has outperformed by 211.13% the S&P500.

Among 4 analysts covering Allergy Therapeutics PLC (LON:AGY), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Allergy Therapeutics PLC had 55 analyst reports since July 23, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Tuesday, July 18 by Numis Securities. The rating was maintained by Panmure Gordon with “Buy” on Friday, July 8. The stock of Allergy Therapeutics plc (LON:AGY) has “Buy” rating given on Tuesday, February 14 by FinnCap. The rating was maintained by Panmure Gordon with “Buy” on Tuesday, September 1. The stock has “Buy” rating by Numis Securities on Wednesday, January 31. Panmure Gordon maintained it with “Buy” rating and GBX 53 target in Thursday, January 19 report. FinnCap maintained Allergy Therapeutics plc (LON:AGY) rating on Wednesday, March 29. FinnCap has “Buy” rating and GBX 43 target. As per Wednesday, January 13, the company rating was maintained by Panmure Gordon. The company was maintained on Thursday, April 21 by Panmure Gordon. The firm earned “Buy” rating on Wednesday, February 1 by Panmure Gordon. See Allergy Therapeutics plc (LON:AGY) latest ratings:

12/02/2018 Broker: FinnCap Rating: Corporate Old Target: GBX 47.00 New Target: GBX 47.00 Maintain
01/02/2018 Broker: FinnCap Rating: Corporate Old Target: GBX 47.00 New Target: GBX 47.00 Maintain
31/01/2018 Broker: Numis Securities Rating: Buy Old Target: GBX 45.00 New Target: GBX 45.00 Maintain
05/12/2017 Broker: Numis Securities Rating: Buy Old Target: GBX 45.00 New Target: GBX 45.00 Maintain
21/11/2017 Broker: FinnCap Rating: Buy Old Target: GBX 47.00 New Target: GBX 47.00 Maintain
20/10/2017 Broker: FinnCap Rating: Buy Old Target: GBX 47.00 New Target: GBX 47.00 Maintain
28/09/2017 Broker: Panmure Gordon Rating: Buy Maintain
28/09/2017 Broker: Numis Securities Rating: Buy Old Target: GBX 45.00 New Target: GBX 45.00 Maintain
28/09/2017 Broker: FinnCap Rating: Buy Old Target: GBX 46.00 New Target: GBX 47.00 Maintain
22/09/2017 Broker: Numis Securities Rating: Buy Old Target: GBX 45.00 New Target: GBX 45.00 Maintain

Among 8 analysts covering Health Insurance Innovations Inc (NASDAQ:HIIQ), 7 have Buy rating, 0 Sell and 1 Hold. Therefore 88% are positive. Health Insurance Innovations Inc had 29 analyst reports since August 13, 2015 according to SRatingsIntel. Canaccord Genuity maintained Health Insurance Innovations, Inc. (NASDAQ:HIIQ) rating on Thursday, December 21. Canaccord Genuity has “Buy” rating and $39.0 target. The rating was downgraded by Raymond James on Thursday, June 9 to “Market Perform”. On Wednesday, November 1 the stock rating was maintained by Cantor Fitzgerald with “Buy”. The stock of Health Insurance Innovations, Inc. (NASDAQ:HIIQ) has “Market Perform” rating given on Monday, June 26 by Raymond James. Craig Hallum maintained Health Insurance Innovations, Inc. (NASDAQ:HIIQ) rating on Thursday, August 3. Craig Hallum has “Buy” rating and $3800 target. The company was maintained on Friday, September 1 by Cantor Fitzgerald. Canaccord Genuity maintained it with “Buy” rating and $3000 target in Wednesday, July 12 report. Lake Street maintained Health Insurance Innovations, Inc. (NASDAQ:HIIQ) rating on Friday, December 30. Lake Street has “Buy” rating and $20 target. The stock of Health Insurance Innovations, Inc. (NASDAQ:HIIQ) earned “Buy” rating by Cantor Fitzgerald on Wednesday, February 14. The stock of Health Insurance Innovations, Inc. (NASDAQ:HIIQ) earned “Buy” rating by Northland Capital on Monday, October 16.

Caprock Group Inc decreased Vanguard World Fds (VDE) stake by 10,588 shares to 2,623 valued at $248,000 in 2017Q3. It also reduced Procter And Gamble Co (NYSE:PG) stake by 6,479 shares and now owns 56,143 shares. Paypal Hldgs Inc was reduced too.

Since August 31, 2017, it had 0 buys, and 8 sales for $2.86 million activity. Wang Sheldon sold $526,000 worth of stock or 20,000 shares. Hershberger Michael D sold $558,384 worth of stock. Another trade for 9,970 shares valued at $360,799 was sold by Telkamp Bruce.

Investors sentiment increased to 1.73 in 2017 Q3. Its up 0.10, from 1.63 in 2017Q2. It is positive, as 25 investors sold HIIQ shares while 19 reduced holdings. 45 funds opened positions while 31 raised stakes. 10.06 million shares or 8.67% more from 9.25 million shares in 2017Q2 were reported. Nationwide Fund holds 6,348 shares. Alps invested in 0% or 23,822 shares. Trexquant Inv Ltd Partnership reported 30,316 shares. Citadel Advisors Llc has 104,469 shares. Wells Fargo & Mn has invested 0% in Health Insurance Innovations, Inc. (NASDAQ:HIIQ). Advisors Asset Mgmt has 9,827 shares for 0% of their portfolio. Tower Cap Ltd (Trc), New York-based fund reported 2,388 shares. Barclays Plc has invested 0% of its portfolio in Health Insurance Innovations, Inc. (NASDAQ:HIIQ). Kennedy Cap Mngmt Inc accumulated 0.02% or 69,733 shares. State Street Corp holds 0% or 183,722 shares in its portfolio. 375,000 were reported by Harvest Cap Strategies Lc. Lyon Street Capital Limited Liability reported 936,747 shares or 5.24% of all its holdings. Advisory Serv Ntwk Lc invested in 73 shares or 0% of the stock. Parallax Volatility Advisers LP reported 28,962 shares. Cannell Cap holds 4.42% in Health Insurance Innovations, Inc. (NASDAQ:HIIQ) or 1.04M shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts